ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New Alzheimer’s drug to slow disease expected to approved

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jul 06, 2023 9:57am

134 Views

Post# 35528965

RE:New Alzheimer’s drug to slow disease expected to approved

Sorry for the multiple posts, but this is the quote that stands out for me....

“The treatments we have right now are just the beginning of a new era,” Honig said. “We hope that we will have treatments that are more efficacious.”

<< Previous

Bullboard Posts

Next >>

Barrick Gold employees detained in Mali amid ongoing dispute